| Advice Pool |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Health and Fitness > Diseases > Hospital Pandemic Flu Planing |
|
Advice Pool - Hospital Pandemic Flu Planing
Since 1997 when the first case of bird flu, or avian flu, was reported to have been spread to humans, health care professionals have been starting to look at wh According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product at type of hospital pandemic flu plans need to be in place to best serve their communities. Hospital administrators in countries around the world have increasi ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in ngly been gathering critical knowledge and information needed to prepare an effective hospital pandemic flu preparedness plan that will address both patient car lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. and employee health needs. Hospitals are responsible for providing a safe and healthful workplace for their employees and for the patients under their care du here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe ring a pandemic event. As part of the preparedness activities, public health agencies and hospitals are more frequently engaging in coordinating and conducting d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro exercises and drills focused on a possible flu pandemic. During a flu pandemic event, hospitals will be responsible for providing the brunt of essential servic ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc es pandemic influenza would require. Hospital administration also must take into consideration that they will the have the dual responsibility of caring for lar easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi e numbers of critically ill patients and of protecting the health of hospital personnel, during a period when resources and staffing are expected to be strained nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically , which makes pandemic influenza hospital policies even more critical to be well thought out and prepared for. As the world health community waits for what it and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ ooking like an inevitable flu pandemic, some are concerned that the chronic nationwide shortage of health care workers in US hospitals could increase. What can ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi be expected during a flu pandemic related to community and patient needs, employee absences, and interrupted supply and delivery schedules must be addressed, a ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a s well as effective ways of managing these challenges during a flu pandemic. Vaccine manufacturers and researchers are doing the foundation work that is necess dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod ry to develop a bird flu vaccine, but an actual vaccine against a pandemic cannot be manufactured until the virus has emerged. Because of concerns about availa cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin ble vaccine and the possibility that health care services may be spread very thin in a pandemic influenza outbreak, personal pandemic preparations must also be tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen onsidered by individuals and families. Sian Griffiths, director of Hong Kong's School of Public Health at the Chinese University, believes that the most effecti t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel ve method for stopping the spread of a bird flu pandemic is really very simple: good hygiene. Careful washing of hands and avoiding touching eyes, nose or mouth ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust can significantly reduce the possible spread of influenza of any type. Also, avoid close contact with those who are already sick or showing symptoms. Covering y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products the mouth and nose with tissue when coughing or sneezing will also help limit the spread. Wash your hands often. While there is no immediate threat of bird fl . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de virus spreading widely into the human population, it is reassuring to be aware that hospital pandemic flu plans are being made. However, because of inherent li elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip mitations in case of a pandemic influenza presentation, it is emphasized that personal pandemic preparations should always be considered a first line of defense tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:
|